Replies to post #70082 on Ayala Pharmaceuticals Inc (ADXS)

[DewDiligence]

ADXS-NEO is using a traditional “3+3” trial design for each of the three cancer indications being tested:

http://onbiostatistics.blogspot.com/2015/01/phase-i-dose-escalation-study-design-3.html [scan down to see flowchart]